Connor Clark & Lunn Investment Management Ltd. Makes New Investment in OptimizeRx Corp. $OPRX

Connor Clark & Lunn Investment Management Ltd. bought a new stake in OptimizeRx Corp. (NASDAQ:OPRX) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 30,944 shares of the company’s stock, valued at approximately $418,000. Connor Clark & Lunn Investment Management Ltd. owned about 0.17% of OptimizeRx as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Blair William & Co. IL lifted its stake in OptimizeRx by 4.9% in the 1st quarter. Blair William & Co. IL now owns 631,031 shares of the company’s stock worth $5,465,000 after purchasing an additional 29,648 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of OptimizeRx in the second quarter valued at approximately $349,000. Rhumbline Advisers lifted its position in OptimizeRx by 10.5% during the first quarter. Rhumbline Advisers now owns 27,785 shares of the company’s stock worth $241,000 after buying an additional 2,636 shares in the last quarter. Whetstone Capital Advisors LLC boosted its stake in OptimizeRx by 11.7% during the first quarter. Whetstone Capital Advisors LLC now owns 1,508,303 shares of the company’s stock worth $13,062,000 after buying an additional 157,880 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in OptimizeRx in the 1st quarter valued at $455,000. 76.47% of the stock is currently owned by institutional investors and hedge funds.

OptimizeRx Price Performance

OptimizeRx stock opened at $13.58 on Friday. OptimizeRx Corp. has a 12-month low of $3.99 and a 12-month high of $22.25. The stock has a market cap of $253.14 million, a P/E ratio of -25.15 and a beta of 1.24. The company has a current ratio of 2.57, a quick ratio of 2.57 and a debt-to-equity ratio of 0.21. The company has a fifty day simple moving average of $18.34 and a 200-day simple moving average of $15.49.

OptimizeRx (NASDAQ:OPRX) last posted its earnings results on Thursday, November 6th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.17. The firm had revenue of $26.07 million during the quarter, compared to analysts’ expectations of $23.83 million. OptimizeRx had a positive return on equity of 4.50% and a negative net margin of 9.42%. OptimizeRx has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. Equities analysts expect that OptimizeRx Corp. will post -0.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on OPRX. Zacks Research upgraded OptimizeRx from a “hold” rating to a “strong-buy” rating in a report on Friday, November 14th. Citigroup reiterated an “outperform” rating on shares of OptimizeRx in a report on Friday, October 10th. Stifel Nicolaus raised their target price on OptimizeRx from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, August 8th. Wall Street Zen upgraded shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, Citizens Jmp lifted their price objective on OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.88.

Insiders Place Their Bets

In other news, Director Patrick D. Spangler sold 11,120 shares of the business’s stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $17.49, for a total value of $194,488.80. Following the completion of the sale, the director directly owned 44,215 shares of the company’s stock, valued at approximately $773,320.35. The trade was a 20.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Stephen L. Silvestro sold 1,620 shares of the firm’s stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $18.75, for a total value of $30,375.00. Following the transaction, the chief executive officer owned 188,916 shares in the company, valued at $3,542,175. This represents a 0.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 5.60% of the stock is owned by insiders.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.